Coeptis Therapeutics (NASDAQ:ZSQR) Shares Down 2.9% – Should You Sell?

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) was down 2.9% during trading on Wednesday . The stock traded as low as $2.97 and last traded at $3.00. 221,953 shares traded hands during mid-day trading, a decline of 31% from the average session volume of 320,146 shares. The stock had previously closed at $3.09.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Coeptis Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Weiss Ratings downgraded Coeptis Therapeutics from a “sell (d-)” rating to a “sell (e-)” rating in a research note on Friday, August 14th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Coeptis Therapeutics has a consensus rating of “Sell”.

Coeptis Therapeutics Stock Down 2.8%

The company has a 50 day moving average of $4.82 and a 200 day moving average of $9.52. The stock has a market capitalization of $162.71 million, a price-to-earnings ratio of -1.88 and a beta of -0.25.

Coeptis Therapeutics (NASDAQ:ZSQR) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.28) earnings per share for the quarter. Coeptis Therapeutics had a negative net margin of 773.72% and a negative return on equity of 49.45%. The company had revenue of $1.58 million during the quarter.

Institutional Investors Weigh In On Coeptis Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC raised its stake in shares of Coeptis Therapeutics by 100.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after purchasing an additional 2,500 shares in the last quarter. Geode Capital Management LLC increased its holdings in Coeptis Therapeutics by 12.6% in the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock valued at $600,000 after buying an additional 4,721 shares during the last quarter. State Street Corp raised its stake in Coeptis Therapeutics by 35.0% during the fourth quarter. State Street Corp now owns 26,830 shares of the company’s stock valued at $382,000 after buying an additional 6,962 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in Coeptis Therapeutics during the 4th quarter worth approximately $259,000. Hedge funds and other institutional investors own 13.88% of the company’s stock.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.